Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.900
+0.030 (1.60%)
Nov 4, 2024, 4:00 PM EST - Market closed
Cardiol Therapeutics Employees
Cardiol Therapeutics had 6 employees as of December 31, 2018.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,572,585
Market Cap
153.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2018 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 185 |
| Repare Therapeutics | 179 |
| Generation Bio Co. | 174 |
| Inovio Pharmaceuticals | 122 |
| EUDA Health Holdings | 106 |
| Compugen | 68 |
| Outlook Therapeutics | 24 |
| Akso Health Group | 9 |
CRDL News
- 13 days ago - Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Newsfile Corp
- 24 days ago - Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option - Newsfile Corp
- 25 days ago - Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares - Newsfile Corp
- 26 days ago - Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Newsfile Corp
- 27 days ago - Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares - Newsfile Corp
- 5 weeks ago - Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis - Newsfile Corp
- 7 weeks ago - Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Newsfile Corp
- 4 months ago - Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders - Newsfile Corp